Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily versus twice-daily vatalanib in previously treated metastatic colorectal cancer
2006-004824-35Phase 2Terminated
- Sponsor
- Schering AG
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vatalanib in metastatic colorectal adenocarcinoma (mCRC), colon adenocarcinoma and rectal adenocarcinoma (2 arms), sponsored by Schering AG. Primary endpoint: Reduction in Ktrans by DCE-MRI at Day 28. Started Jan 2007; status: terminated.
02
Drugs
vatalanib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on 2006-004824-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004824-35.